Search

Your search keyword '"Cappelletti, V."' showing total 295 results
Start Over Author "Cappelletti, V."
295 results on '"Cappelletti, V."'

6. 26P ctDNA prognostic and diagnostic value for recurrence in patients with early-stage breast cancer: A systematic review and meta-analysis

Author

Marta, G. Nader, primary, Monforte, M., additional, Cinquini, M., additional, Agostinetto, E., additional, Branco, D. Martins, additional, Fontsa, M. Langouo, additional, Ignatiadis, M., additional, Torri, V., additional, Apolone, G., additional, Cappelletti, V., additional, Pruneri, G., additional, de Azambuja, E., additional, and Di Cosimo, S., additional

Published
2023
Full Text
View/download PDF

7. 51P Clinical and biological significance of low ERBB2 expression in ductal carcinoma in situ (DCIS) of the breast

Author

Ciniselli, C.M., primary, Verderio, P., additional, Baili, P., additional, Sant, M., additional, De Braud, F.G.M., additional, Folli, S., additional, Scaperrotta, G., additional, De Santis, M.C., additional, Duroni, V., additional, Apolone, G., additional, Vingiani, A., additional, Cappelletti, V., additional, Pruneri, G., additional, and Di Cosimo, S., additional

Published
2023
Full Text
View/download PDF

9. 2MO Development of a prognostic gene-expression signature for early stage HER2-positive breast cancer patients

Author

Di Cosimo, S., primary, Ciniselli, C.M., additional, Sotiriou, C., additional, Pogue-Geile, K., additional, Fumagalli, D., additional, de Azambuja, E., additional, Venet, D., additional, De Cecco, L., additional, Pong, N., additional, Cappelletti, V., additional, Tagliabue, E., additional, Wang, Y., additional, Saura Manich, C., additional, Nuciforo, P.G., additional, Kuemmel, S., additional, Pusztai, L., additional, Daidone, M.G., additional, Pizzamiglio, S., additional, Pruneri, G., additional, and Verderio, P., additional

Published
2022
Full Text
View/download PDF

12. Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

Author

Mennitto, A., primary, Verzoni, E., additional, Cognetti, F., additional, Miceli, R., additional, Milella, M., additional, Mosca, A., additional, Chiuri, V. E., additional, Bearz, A., additional, Morelli, F., additional, Ortega, C., additional, Atzori, F., additional, Donini, M., additional, Claps, M., additional, Guadalupi, V., additional, Sepe, P., additional, Cappelletti, V., additional, de Braud, F. G., additional, and Procopio, G., additional

Published
2021
Full Text
View/download PDF

17. Clinical outcome after radical metastasectomy in renal cell carcinoma: Results from a randomized phase 2 study

Author

Procopio, G., primary, Apollonio, G., additional, Cognetti, F., additional, Miceli, R., additional, Milella, M., additional, Mosca, A., additional, Chiuri, V.E., additional, Bearz, A., additional, Morelli, F., additional, Ortega, C., additional, Atzori, F., additional, Donini, M., additional, Ratta, R., additional, Raimondi, A., additional, Claps, M., additional, Martinetti, A., additional, Capitanio, U., additional, De Braud, F.G., additional, Cappelletti, V., additional, and Verzoni, E., additional

Published
2019
Full Text
View/download PDF

19. A Case Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic and Tractable Biomarkers in Male Breast Cancer

Author

Humphries, MP, Rajan, SS, Droop, A, Suleman, CAB, Carbone, C, Nilsson, C, Honarpisheh, H, Cserni, G, Dent, J, Fulford, L, Jordan, LB, Jones, JL, Kanthan, R, Litwiniuk, M, Di Benedetto, A, Mottolese, M, Provenzano, E, Shousha, S, Stephens, M, Walker, RA, Kulka, J, Ellis, IO, Jeffery, M, Thygesen, HH, Cappelletti, V, Daidone, MG, Hedenfalk, IA, Fjällskog, M-L, Melisi, D, Stead, LF, Shaaban, AM, and Speirs, V

Abstract

Purpose: Breast cancer (BC) affects both genders, but is understudied in men. Although still rare, male BC is being diagnosed more frequently. Treatments are wholly informed by clinical studies conducted in women, based on assumptions that underlying biology is similar. Experimental design: A transcriptomic investigation of male and female BC was performed, confirming transcriptomic data in silico. Biomarkers were immunohistochemically assessed in 697 MBCs (n=477, training; n=220, validation set) and quantified in pre- and post-treatment samples from a male BC patient receiving Everolimus and PI3K/mTOR inhibitor. Results: Gender-specific gene expression patterns were identified. eIF transcripts were up-regulated in MBC. eIF4E and eIF5 were negatively prognostic for overall survival alone (Log rank; p=0.013; HR=1.77, 1.12-2.8 and p=0.035; HR=1.68, 1.03-2.74, respectively), or when co-expressed (p=0.01; HR=2.66, 1.26-5.63), confirmed in the validation set. This remained upon multivariate Cox regression analysis (eIF4E p=0.016; HR 2.38 (1.18-4.8), eIF5 p=0.022; HR 2.55 (1.14-5.7); co-expression p=0.001; HR=7.04 (2.22-22.26)). Marked reduction in eIF4E and eIF5 expression was seen post BEZ235/Everolimus, with extended survival. Conclusions: Translational initiation pathway inhibition could be of clinical utility in male BC patients overexpressing eIF4E and eIF5. With mTOR inhibitors which target this pathway now in the clinic, these biomarkers may represent new targets for therapeutic intervention, although further independent validation is required.

Published
2017

20. Use of red clover in premenopausal breast cancer patients receiving hormonal adjuvant treatment: Biological and clinical implications from a randomized clinical trial

Author

Ferraris, C., primary, Ballestra, B., additional, Cappelletti, V., additional, Listorti, C., additional, Miodini, P., additional, Pulice, I., additional, Mariani, L., additional, Ferrari, E., additional, Gambaro, A., additional, Maugeri, I., additional, Martelli, G., additional, and Folli, S., additional

Published
2018
Full Text
View/download PDF

21. Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy

Author

Procopio, G., primary, Cognetti, F., additional, Miceli, R., additional, Milella, M., additional, Mosca, A., additional, Chiuri, V.E., additional, Bearz, A., additional, Morelli, F., additional, Ortega, C., additional, Atzori, F., additional, Passalacqua, R., additional, Ratta, R., additional, de Braud, F.G.M., additional, Cappelletti, V., additional, and Verzoni, E., additional

Published
2018
Full Text
View/download PDF

24. FastGC PTR-ToF-MS analysis of yeast VOCs

Author

Iuliia Khomenko, Stefanini, I., Luca Cappellin, Cappelletti, V., Pietro Franceschi, Märk, T. D., and Franco Biasioli

Subjects
Settore CHIM/01 - CHIMICA ANALITICA
Published
2016

28. Identification of microRNAs targeting the DNA damage response in breast cancer

Author

BISSO, ANDREA, FALESCHINI, MICHELA, ZAMPA, FEDERICO, DEL SAL, GIANNINO, Piazza, S., Santarpia, L., Cappelletti, V., Daidone, M. G., Agami, R., ABCD, Bisso, Andrea, Faleschini, Michela, F., Zampa, S., Piazza, L., Santarpia, V., Cappelletti, M. G., Daidone, R., Agami, G., Del Sal, ABCD e SIBBM, Zampa, Federico, Piazza, S., Santarpia, L., Cappelletti, V., Daidone, M. G., Agami, R., and DEL SAL, Giannino

Subjects
breast cancer, atm, microRNA, miR-181, microRNA, miR-181, ATM
Abstract

Several in vivoand in vitro data demonstrated that the DNA damage response (DDR) plays a crucial role in tumorigenesisacting as an anti-cancer barrier. Indeed, cells respond to DNA breaks caused by both exogenous (e.g. chemicals, chemotherapeutics) and endogenous (e.g. deregulated function of oncogenes) sources of DNA damages by properly triggering the activation of the DDR. The latter involves the recruitment of DNA repair proteins to sites of damage and the activation of checkpoint mechanisms to slow down cell cycle progression, thus allowing DNA damage repair or, if the damage could not be repaired, leading to apoptosis or cellular senescence. As a consequence, alterations of DDR functionality have a deep impact on cell proliferation, survival, genomic instability and tumorprogression. microRNAs(miRNAs) are small non coding RNAs that finely regulate gene expression by binding the 3’UTR of their target mRNAs, thus altering theirtranslation, stability and localization. It has been shown that several miRNAsmodulate critical cellular processes deregulated in cancer, acting either as oncogenesor tumorsuppressors. In the present study, we focused on the identification of miRNAsas new modulators of DNA damage activated signalingin several normal and transformed breast cancer cells. In particular, we discovered that miR-181 family acts as a modulator of the levels of ATM (ataxia telangiectasiamutated) kinase, one of the most important proteins involved in sensing DNA double strand breaks and activating DDR. The role of miR-181 family in the DDR pathway, its involvement in the induction of cellular senescence triggered by oncogenicstress (OIS) and its relevance in breast cancer will be presented.

Published
2011

38. Journals under threat. A joint response from History of Science, Technology and Medicine editors

Author

Fox, R., Andersen, H., Ariew, R., Feingold, M., Bag, A. K., Barrow-Green, J., Dalen, B., Benson, K., Beretta, M., Blay, M., Cornelius Borck, Bowker, G., Star, S. L., Bucciantini, M., Camerota, M., Buchwald, J., Gray, J., Cappelletti, V., Cimino, G., Clark, M., Keller, A., Cline, R., Clucas, S., Gaukroger, S., Cook, H., Hardy, A., Corry, L., Métraux, A., Renn, J., Dolan, B., Luckin, B., Duerbeck, H., Orchiston, W., Epple, M., Hård, M., Rheinberger, H. J., Roelcke, V., French, S., Farber, P., Fissell, M., Packard, R., Good, J., Hackmann, W., Halleux, R., Holmqvist, B., Hoskin, M., Inkster, I., Spada, M. F., Jardine, N., Levere, T., Lightman, B., Lüthy, C., Lynch, M., Mccluskey, S., Ruggles, C., Morris, P., Nelson, E. C., Nicholson, I., Olesko, K., Peréz, L., Morus, I. R., Rigden, J., Stuewer, R. H., Samsó, J., Schaffer, S., Schappacher, N., Strom, C., Unschuld, P., Weingart, P., Zamecki, S., and Zuidervaart, H.

Subjects
Europe, Humans, Periodicals as Topic, Netherlands
Published
2012

41. Journals under threat: a joint response from history of science, technology and medicine editors

Author

Cook, H., Hardy, A., Andersen, H., Ariew, R., Feingold, M., Bag, A. K., Barrow-Green, J., Dalen, B., Benson, K., Beretta, M., Blay, M., Bleker, J., Stolberg, M., Cornelius Borck, Bowker, G., Star, S. L., Bucciantini, M., Camerota, M., Buchwald, J., Gray, J., Cappelletti, V., Cimino, G., Carson, C., Clark, M., Keller, A., Cline, R., Clucas, S., Gaukroger, S., Corry, L., Métraux, A., Renn, J., Dolan, B., Luckin, B., Duerbeck, H., Orchiston, W., Epple, M., Hård, M., Rheinberger, H. J., Roelcke, V., Farber, P., Fissell, M., Packard, R., Fox, R., Frasca-Spada, M., French, S., Good, J., Hackmann, W., Halleux, R., Holmqvist, B., Home, R., Hoskin, M., Inkster, I., Jardine, N., Levere, T., Lightman, B., Lüthy, C., Lynch, M., Mccluskey, S., Ruggles, C., Morris, P., Morus, I. R., Nelson, E. C., Nicholson, I., Olesko, K., Pérez, L., Rigden, J., Stuewer, R. H., Samsó, J., Schaffer, S., Schappacher, N., Staudenmaier, J., Strom, C., Unschuld, P., Weingart, P., Zamecki, S., and Zuidervaart, H.

Subjects
Technology, Germany, Science, Humans, History of Medicine, Journal Impact Factor, Periodicals as Topic, Editorial Policies
Published
2009

43. Circulating Tumor Cells (CTCS) as Prognostic Biomarker in Patients with Advanced Chemorefractory, Ras Wild-Type Colorectal Cancer (CRC) Treated with Cetuximab or Panitumumab

Author

Musella, V., primary, Pietrantonio, F., additional, Di Buduo, E., additional, Bossi, I., additional, Iacovelli, R., additional, Maggi, C., additional, Martinetti, A., additional, Sottotetti, E., additional, Di Bartolomeo, M., additional, de Braud, F., additional, and Cappelletti, V., additional

Published
2014
Full Text
View/download PDF

44. 791 Phase 2 study of neoadjuvant sorafenib plus cisplatin and gemcitabine (S-CG) for patients with muscle-invasive transitional cell carcinoma of the bladder (MIBC): Results at the end of first stage (NCT01222676)

Author

Necchi, A., primary, Mariani, L., additional, Giannatempo, P., additional, Fina, E., additional, Nicolai, N., additional, Pennati, M., additional, Zaffaroni, N., additional, Farè, E., additional, Piva, L., additional, Biasoni, D., additional, Catanzaro, M., additional, Torelli, T., additional, Stagni, S., additional, Maffezzini, M., additional, Colecchia, M., additional, Paolini, B., additional, Cappelletti, V., additional, Daidone, M.G., additional, Gianni, A.M., additional, and Salvioni, R., additional

Published
2014
Full Text
View/download PDF

45. 784 Quantification and molecular profiling of circulating tumour cells (CTCs) in urothelial cancer (UC) before and during systemic treatment: Implications across the clinical stages

Author

Necchi, A., primary, Fina, E., additional, Giannatempo, P., additional, Colecchia, M., additional, Iacona, C., additional, Farè, E., additional, Nicolai, N., additional, Salvioni, R., additional, Gianni, A.M., additional, Mariani, L., additional, Daidone, M.G., additional, and Cappelletti, V., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results